Podcasts about Grade

One of the best jockeys of his generation and a multiple Grade 1 winner, Aidan Coleman joins Emmet Kennedy and Adam Mills to preview the key novice races at the 2026 Cheltenham Festival. The focus begins with a highly competitive running of the Arkle Novice Chase, where Lulamba, Kopek Des Bordes, Romeo Coolio, Kargese, Irish Panther and Steel Ally are set to clash. Aidan reveals the horse he would most like to ride and gives his insight into how the race may unfold. Attention then turns to the Brown Advisory Novices' Chase, with a strong field including Final Demand, Kaid d'Authie, The Big Westerner, Wendigo, Western Fold, Kitzbuhel, Oscars Brother and Sixmilebridge. The team assess the leading contenders and put forward a 16/1 betting angle in the 3m1f contest. The discussion then shifts to the novice hurdlers, with leading contenders Old Park Star, Mighty Park, El Cairos, Mydaddypaddy, Idaho Sun and Sober Glory analysed in detail, before a deep dive into the Turners Novice Hurdle featuring No Drama This End, Skylight Hustle, Talk The Talk, Act Of Innocence and others.

What if the real reason you're not showing up online isn't strategy… but fear of judgment?In this episode, I'm joined by mindset coach and business strategist Ivana Ivanek to unpack the real reason so many brilliant, mission-driven women hold back from visibility.We talk about the fear of societal rejection, outgrowing old circles, and why you're overthinking your third-grade cousin's opinion instead of focusing on the people who actually need your work.If you've ever felt cringe hitting “post,” worried about who's watching your stories, or watered yourself down online… this conversation will shift something in you.This is about personal branding, yes.But more than that? It's about identity, courage, and stepping into the leader your business needs you to be.If you LOVED this episode, make sure you share this on your Instagram stories and tag us @contentqueenmariah and @ivanaivanek_.⁠⁠⁠LEARN THE DETAILS OF A CONTENT STRATEGY WITH MY FREE AUDIO GUIDE⁠⁠⁠KEY EPISODE TAKEAWAYS

This week on VG Pulse, we’ve got a whole pile of stupid to go over! We start off with side notes of new phones and giant movie posters, before we dive into the stupid where we discuss Discord being stupid! Oh why do companies have to be stupid… after the stupid, we discuss the rocky future of Microsoft, Toyota making their own weird game engine, and some incredibly upsetting losses in the legacy gaming sphere these past few weeks. After the news we realize we’ve gone very long on this one, and skip right on to finishing off with talk of anime!! All this and more up next on VGP … Continue reading "VG Pulse 430: NASA Grade Engineering"

Two leaders, two visions, two itineraries. Prime Minister Mark Carney is once again travelling abroad to strengthen Canada's trading relationships with fellow middle powers like India, Japan and Australia. How much sway does Canada hold in this new geopolitical era? Anne-Marie Slaughter, former Obama-era senior U.S. State Department director, joins The House to weigh in on this middle-power moment.And Pierre Poilievre is headed to Europe in his first official overseas trip as Leader of the Opposition, following a speech that laid out the Conservative vision for tackling a protectionist United States. Political insiders Marci Surkes and Kate Harrison take a look at both big trips, and the stakes for both parties.Next: OpenAI was the focus of intense scrutiny this week after it was revealed the ChatGPT developer did not inform police about troubling content from an online account belonging to the Tumbler Ridge shooter. The House checks in with The Logic's Murad Hemmadi about whether big tech companies can be trusted to regulate themselves.Then, as the world's youngest generations are set to bear the brunt of today's decisions, some governments around the world are taking steps to ensure they have a champion — and Canadian advocates want Ottawa to do the same. House producer Benjamin Lopez Steven speaks with Wales' Future Generations Commissioner Derek Walker, as well as Paul Kershaw of Generation Squeeze, Ontario Senator Rosemary Moodie and a classroom of Grade 8 students about whether the Welsh model could work in Canada.And as Russia's war on Ukraine grinds on, and peace talks remain deadlocked, Canada's Ambassador to Ukraine Natalka Cmoc speaks with guest host Tom Parry about a difficult winter in Kyiv and the horrors she's heard on the ground from Ukrainians.This episode features the voices of:Anne-Marie Slaughter, CEO of think tank New America and former senior official at the U.S. State DepartmentMarci Surkes, former senior advisor to Justin Trudeau and chief strategy officer at Compass RoseKate Harrison, Conservative strategist and vice chair at Summa StrategiesMurad Hemmadi, AI reporter for The LogicDerek Walker, Future Generations Commissioner for WalesKatie Richmyre, Grade 8 teacher at St. Mother Teresa High SchoolPaul Kershaw, founder of Generation SqueezeSenator Rosemary MoodieNatalka Cmoc, Canada's ambassador to Ukraine

2.27.26, Kevin Sheehan asks callers for their thoughts on what they think Dan Quinn's A+ grade on the NFLPA team report card means for how much faith the Commanders players have in him.

2.27.26 Hour 3, Kevin Sheehan asks callers for their thoughts on what they think Dan Quinn's A+ grade on the NFLPA team report card means for how much faith the Commanders players have in him. Kevin Sheehan and Producer Max recaps some of the standout NFL Combine showings and recent news in the NFL.

Join NFL Legends James "Deebo" Harrison and Joe Haden as they react to the Pittsburgh Steelers horrible grade in the NFLPA Report Cards, whether the Steelers should target Ty Simpson in the 2026 NFL Draft, Fernando Mendoza choosing not to throw at the NFL Scouting Combine and much more! Download the PrizePicks app today and use code DEEBOJOE to get $50 in lineups after you play your first $5 lineup! https://prizepicks.onelink.me/LME0/DEEBOJOE Timeline:00:00 - Joe's Mexico Experience15:45 - NFLPA Report Cards41:35 - Steelers meet with Ty Simpson (Timestamps may vary based on advertisements.) #Club #NightcapSee omnystudio.com/listener for privacy information.

Mark and Tommy Football talk about the Steelers and their failing grades in the latest report card. Vince Trocheck joins the show to talk about winning olympic gold. See omnystudio.com/listener for privacy information.

Willard and Dibs discuss the job that Steve Kerr has done this season.

Breaking down the survey results and what the fan-related critique really means.

Mike Johnson, Ali Mac, and Beau Morgan react to the NFLPA's annual survey and report grades getting leaked last night, react to the Atlanta Falcons' NFLPA report card grades, react to Falcons new Head Coach Kevin Stefanski getting a C minus grade for this past season as the Cleveland Browns' Head Coach, and talk about how Kevin Stefanski's NFLPA report card grade isn't good, but isn't all bad either.

Mike Johnson, Ali Mac, and Beau Morgan continue to react to the NFLPA's annual survey and report grades getting leaked last night, continue to react to the Atlanta Falcons' NFLPA report card grades, continue to react to Falcons new Head Coach Kevin Stefanski getting a C minus grade for this past season as the Cleveland Browns' Head Coach, and explain why they think the Browns quarterback controversy last season may've played a part in Kevin Stefanski's C minus grade.

HR2 - Kevin Stefanski's situation in Cleveland a lot to do with NFLPA report card grade In hour two Mike Johnson, Ali Mac, and Beau Morgan continue to react to the NFLPA's annual survey and report grades getting leaked last night, continue to react to the Atlanta Falcons' NFLPA report card grades, continue to react to Falcons new Head Coach Kevin Stefanski getting a C minus grade for this past season as the Cleveland Browns' Head Coach, explain why they think the Browns quarterback controversy last season may've played a part in Kevin Stefanski's C minus grade, play a round of Fair or Foul for the halftime portion of the show, discuss if they think the Falcons will trade back from the 48th overall pick, talk about the push to bring NHL hockey back to Atlanta happening again after the U.S. Men's and Women's hockey teams brought home gold in this year's Winter Olympics in Milan, and then close out hour two by reacting to the latest news, rumors, and reports in the NFL as they go In The Huddle.

Louie & Barry are back with their weekly SoCal Saturday preview!The Grade 2 Buena Vista is the feature.Check out our friends at AMWAGER! They have a 100% deposit match for new customers up to $150.

David Aragona and Gino Buccola preview Saturday's All-Stakes Pick 5, headlined by the Grade 2 Fountain of Youth at Gulfstream Park.

Ashley Mailloux and Mike Beer preview Sunday's Late Pick 5, headlined by the Grade 2 Rebel Stakes at Oaklawn Park.

Mike Schopp reacts to the Bills having their field as their worst grade on the NFLPA report cards

More calls and how did the Lions grade out as an organizationSee omnystudio.com/listener for privacy information.

Aaron chats with Packers fans worldwide from the NFL Combine about the team's tumble down the rankings in the NFL Players Association annual report cards.

Weapons Grade on Sub FM 24th February 2026 - https://www.sub.fm

Dr. Bishal Gyawali and Dr. Tessa Cigler share the new, comprehensive, evidence-based update of the ASCO guideline on the use of hematopoietic colony-stimulating factors in patients with cancer. They discuss recommendations on primary prophylaxis, secondary prophylaxis, and treatment of febrile neutropenia along with stem cell mobilization, efficacy, safety, duration, dosing, and administration of CSFs – including biosimilars. They highlight where it is appropriate to use a CSF, and importantly, when not to use a CSF. They touch on the significance of individual patient considerations and cost implications, and future work to refine the risk factors for the development of complications of febrile neutropenia. Read the full guideline, "White Blood Cell Growth Factors: ASCO Guideline Update" at www.asco.org/supportive-care-guidelines TRANSCRIPT This guideline, clinical tools and resources are available at www.asco.org/supportive-care-guidelines. Read the full text of the guideline and review authors' disclosures of potential conflicts of interest in the Journal of Clinical Oncology,  https://ascopubs.org/doi/10.1200/JCO-25-02938     Brittany Harvey: Hello and welcome to the ASCO Guidelines podcast, one of ASCO's podcasts delivering timely information to keep you up to date on the latest changes, challenges, and advances in oncology. You can find all the shows, including this one, at asco.org/podcasts. My name is Brittany Harvey, and today I'm interviewing Dr. Bishal Gyawali from Queen's University in Kingston, Ontario, Canada, and Dr. Tessa Cigler from Weill Cornell Medicine in New York, New York, co-chairs on "White Blood Cell Growth Factors: ASCO Guideline Update." Thank you for being here today, Dr. Gyawali and Dr. Cigler. Dr. Bishal Gyawali: Thank you very much for having me. It's a pleasure. Dr. Tessa Cigler: Hi there. Nice to be here as well. Brittany Harvey: Great. And then before we discuss this guideline, I'd like to note that ASCO takes great care in the development of its guidelines and ensuring that the ASCO Conflict of Interest Policy is followed for each guideline. The disclosures of potential conflicts of interest for the guideline panel, including Dr. Cigler and Dr. Gyawali, who have joined us here today, are available online with the publication of the guideline in the Journal of Clinical Oncology, which is linked in the show notes. So then I'd like to dive into the guideline that we're here today to talk about. So first, what prompted an update to this guideline on the use of hematopoietic colony-stimulating factors in patients with cancer, and what is the scope of this updated guideline? Dr. Bishal Gyawali: The last version of the guidelines from ASCO on this topic was back in 2015, so it has been more than a decade since ASCO had a guideline on the use of G-CSF in patients with cancer receiving treatment. So it was due for an update because there has been a lot more evidence based on not necessarily new drugs, but evidence for proper timing of these agents and the duration of these agents, as well as there have been a lot of new biosimilars, and there are questions about are these biosimilars equivalent or how do we choose among these different options. One is that content of the evidence that has evolved over time in the last decade, but also I think the last time we had these guidelines, the ASCO guidelines were not incorporated to have those evidence GRADE tables. So the quality of the ASCO guidelines itself has evolved over the years, so we wanted to have a new version of the guideline that includes not only the new evidence, but also contains those evidence GRADE tables that will help to quantify the benefits. And so I think it was high time, and even more than that, the newer ASCO guidelines for any guideline, they also include considerations of cost, access, equity, and all these factors that were not included in the previous version of the guideline. So I think it's only natural that with time the guideline should also evolve. Dr. Tessa Cigler: I agree completely, and just as a framework, as we all know, neutropenia and its complications, including febrile neutropenia and infections, are still an important toxicity of many myelosuppressive chemotherapies. And these neutropenic complications do require prompt evaluation and treatment and often hospitalization, and we know that hematopoietic colony-stimulating factors, which I'm going to refer to as growth factors, can reduce the duration and severity of neutropenia and the risk of febrile neutropenia, so it remains an important topic in the practice of clinical oncology. Brittany Harvey: Absolutely. It's an important topic for both clinicians and for patients who are receiving treatment for their cancer. And as you said, there was a substantial amount of literature to review here and updating everything to be in line with the GRADE evidence rating system, so there was a lot of work that you both put into this. So then next, I'd like to review the key recommendations of this guideline by clinical question. So first, what factors did the expert panel identify that should influence the decision to administer primary prophylaxis of febrile neutropenia with a CSF? Dr. Bishal Gyawali: Yeah, so I think that constitutes one of the most important recommendations in our guidelines about primary prophylaxis with G-CSF. And this is important because not only it's about when to use it, it's also about when not to use it, as in the ASCO "Choosing Wisely" campaign has also made some recommendations about this. So our guideline recommendations are also aligned with that. So first of all, we recommend that primary prophylaxis with G-CSF is recommended when the risk of febrile neutropenia because of the chemotherapy regimen is equal to or more than 20% unless an alternative chemotherapy regimen with comparable efficacy and safety that does not need G-CSF is available. And the quality of evidence to make this recommendation is high, so we give a strong strength of recommendation for this. Having said that, even for patients where the risk of febrile neutropenia is not necessarily 20%, it's a little lower, but because of other patient-related factors, the patient is at a higher risk of complications from febrile neutropenia, such as age, comorbidities, and other factors, in such case primary prophylaxis with G-CSF should be offered. And we also make a recommendation that if G-CSF is not affordable or available, then antibiotic prophylaxis can also be offered, but the evidence quality for this is low, and the strength of recommendation is very conditional. A couple of things to highlight here would be that, I think Dr. Cigler can attest to that, we ran into lots of problems about finding the data for the evidence base to say what are the patient-related factors that actually make them at a higher risk of febrile neutropenia, you know, like how did that 20% benchmark come about? Why 20%? Or when we say even if it's less than 20%, if based on other comorbidities, if the risk is higher, we tried to dig into that evidence. For example, we're talking about our "Box 1" in the guideline, what is the evidence for each item we have included under that "Box 1"? And we tried to do a lot of search to find the evidence for that, and some of them do have strong evidence, and that will tie into our future research ideas as well. And some of them actually don't have such solid evidence too, so that was one of the reasons why we ran into lots of problems about how do we quantify whether someone is at a high risk of febrile neutropenia and where that 20% benchmark comes from. Dr. Tessa Cigler: And definitely, because there's not very clear data, our guidelines definitely leave room for physician discretion in all these situations. Brittany Harvey: Absolutely. I find that in a lot of these guidelines the key point is that there's a lot of shared decision-making with patients after talking through what risk factors they may have and what is best for them in their individual clinical scenario. So then moving on to secondary prophylaxis, what factors did the expert panel identify that should influence the decision to administer secondary prophylaxis of febrile neutropenia with a CSF? Dr. Tessa Cigler: So for patients who've already experienced a neutropenic complication from a previous cycle of chemotherapy, the question is which patients should then receive prophylactic G-CSF for subsequent cycles of chemotherapy. And without a lot of evidence again to guide us, the panel really felt strongly that secondary prophylaxis should be used when a treatment delay or when a reduced dose of chemotherapy would be thought to compromise cure rates or survival outcomes. We do note that in many situations, certainly a dose reduction or a delay would be a very reasonable alternative or an additional strategy to G-CSF administration. Dr. Bishal Gyawali: Yeah, I think it's more like if there is going to be compromise in outcomes without using G-CSF, as in if we can't maintain the dose intensity and that's going to lead to inferior outcomes, then we should. But if we can reduce the dose intensity and treatment frequency and still have the same outcomes, then I guess in simple words, we're just trying to say use it when it's absolutely needed, or you can also look into other alternatives that might not need G-CSF but you could maintain the same outcomes. Brittany Harvey: Understood. It's helpful to review those options for clinicians and showing that there's not just one way to address potential neutropenic complications for later cycles of chemotherapy. So then following those recommendations for prophylaxis, what does the expert panel recommend regarding CSFs for the treatment of febrile neutropenia? Dr. Bishal Gyawali: This is an important question because this ties strongly with the "Choosing Wisely" campaign. In other words, primary and secondary prophylaxis we talked about when CSF should be used; here we make a sort of negative recommendation in that we say when CSF should not be used, because this is where we see most overuse or overtreatment with G-CSF. So first, we say that we should not be using a CSF routinely simply because a patient has neutropenia. If they are afebrile but they only have neutropenia, we recommend against using CSF just to boost neutrophil counts; that's not a meaningful metric. Then the second recommendation we make is CSF should not be routinely used as an adjunctive treatment with antibiotic therapy for patients with fever and neutropenia. So the first one was neutropenia, no fever, don't use it. The second one is okay, there is neutropenia and fever, but the treatment for that is use of antibiotic therapy, and so in such situations routinely we should not be using G-CSF just to boost the neutrophil count. And that is tied on to the third recommendation where if the patient has fever and neutropenia but is also at a very high risk for infection-related complications or who have other prognostic factors that we think will lead to poor outcomes for the patient, then in such situations, a CSF can be used as an adjunctive treatment. But we talk about the data in the manuscript, but the data show that the most that this will do is reduce the days of hospitalization by a couple of days. It actually does not have any data that it's going to improve the mortality rates. So as of now, we use the word "may be offered," it's not "should be offered," it's "may be offered" if there are other factors that we think will make the patient at the very poor risk of mortality outcomes, and the evidence quality here therefore is low and our strength of recommendation is conditional. And we also have a box that lists those items that we think might be associated with poor prognosis for the patients, but again the data for those, are they really hard evidence? No. And that is also tied with our future research recommendation that we should study more about these factors that might lead to these poor outcomes. Dr. Tessa Cigler: And again, allowing for discretion of the treating physician. Brittany Harvey: Absolutely. It's just as important to know when not to use CSFs routinely, and those risk factor boxes that you mentioned are available in the full manuscript along with the full list of recommendations, and our listeners can refer to that; a link will be in the show notes of the episode . Dr. Tessa Cigler: Just so you know, the panel, we really discussed those criteria a lot and agonized over them and gave you our best recommendations. Brittany Harvey: Definitely, and it sounds like there was varying degrees of evidence to support a lot of those risk factors, and so it's really important that the evidence supports those, but also there was expert consensus of the panel in reviewing each of those factors individually to come up with recommendations that can be applicable for all clinicians. Dr. Bishal Gyawali: If I may add, we're proud of our panel because I think our panel is quite inclusive of people representing different specialties within cancer care, as in we had radiation oncologist, we had infectious disease expert, pharmacists, and most importantly, we also had patient partners. Brittany Harvey: Absolutely. Having a multidisciplinary panel is really important for each and every guideline. So then, this is probably relevant now, but addressing a few more specific sections addressed in the guideline, what is the role of CSFs as adjuncts to progenitor cell transplantation? Dr. Tessa Sigler: Great question, and so, as solid tumor oncologists, Dr. Gyawali and I really leaned heavily on our hematology experts within the panel. The panel decided that a CSF should be used alone after chemotherapy or in combination with a CXCR4 inhibitor to mobilize peripheral blood progenitor cells. Clearly the choice of mobilization strategy depends on the type of cancer and the type of transplantation. The panel noted that a CSF should be routinely administered after autologous stem cell transplantation to reduce the risk of severe neutropenia, and that a CSF may be administered after allogeneic stem cell transplant to reduce the duration of severe neutropenia. Again, this last recommendation has not a lot of evidence to support it, and so we kind of tempered our language that it may be administered or can be considered based on clinical judgment of the physician and the clinical status of the patient. Brittany Harvey: And that really highlights the need for a multidisciplinary panel, because as you are solid tumor oncologists, you need the hematologists to make recommendations for all sorts of patients and make sure that these guidelines are comprehensive.   So then moving on to another smaller subset population, for patients receiving concomitant chemotherapy and radiation therapy, are CSFs recommended? Dr. Bishal Gyawali: I think there is very little evidence for patients who are receiving radiation therapy alone, so there is no evidence to suggest the use of CSF in patients with radiation therapy alone. The bigger question is in patients who are receiving both chemo and radiation together, chemoradiotherapy. In those patients, up until now, the classical recommendation has been to avoid G-CSF use. I think in our updated guidelines we discuss a couple newer trials that are trying to address this issue, but in the totality of evidence, we still stick with the same recommendation as before, which is CSFs are not recommended in patients receiving concomitant chemotherapy and radiation therapy, especially those involving the mediastinum because the biggest evidence of harm is for these patients. Dr. Tessa Cigler: I agree completely. Brittany Harvey: Definitely. It's important to recognize when that balance of benefits and harms leans more towards harms, and so that this should not be recommended for those patients. So there are several different CSFs that are recommended in the guideline, including biosimilars. So do the recommended CSFs differ in efficacy or safety? Dr. Tessa Cigler: So as supported by evidence, and the panel all agreed, that the various forms of CSFs, including the biosimilars, really have the same evidence for efficacy and for safety, and that the choice of agent really should depend on cost, availability, accessibility, patient convenience, and sometimes disease subtypes and treatment regimens. But, in essence, these can be used interchangeably without concern for efficacy or toxicity differences. Dr. Bishal Gyawali: I completely agree. I think in terms of efficacy outcomes, I don't think there is anything to choose between these agents. The choice between these agents would largely depend on different patient and treatment-related factors: cost, availability, affordability, feasibility. We even discuss things like where does the patient live, as in how frequently the patient can commit to the cancer center, and we also discussed things like even for the daily shots of filgrastim, patients can be taught and they can get it by themselves at home. So we discussed all these factors, but in a nutshell, the choice within these agents primarily depends not on efficacy factors, but simply based on all these other factors that are equally important but which can lead to informed decision-making about what is best for a given patient. But we mention it explicitly that the biosimilars, there is nothing to choose between them, especially the biosimilars; it's about price competition and what you can get at an affordable rate. Brittany Harvey: Understood. It's great to have many different options for patients so that there's something that can work for them based off access, cost, and all these factors that you listed. As you mentioned, it may be easier for some patients to get their treatment at home rather than in clinic, and so having different options and reviewing those with patients is very important. Dr. Bishal Gyawali: As we are having this conversation, I'm thinking that we might be a very unique guideline in that I don't think in many other settings you have this many options that you are asking about, you know, choices between equally good options and making decisions based on cost. I don't think there are any other areas in oncology where we have the privilege of making these decisions based on cost and convenience and all these factors, as well as we might be one of those guidelines where we have, as discussed before, so many recommendations about when not to do things and trying to promote judicial use of treatments. Dr. Tessa Cigler: As you might imagine, our panel discussions were very lively. Dr. Bishal Gyawali: Yes. But Dr. Cigler, do you recall any other guideline where there is so much discussion about when not to use things and how we have so many biosimilar options and we can choose the one that's most appropriate? I don't recall any other. Dr. Tessa Cigler: I agree with you. Brittany Harvey: It's certainly a unique guideline in that regard. So we'll move into the last clinical question that the expert panel addressed. But what does the expert panel recommend for the initiation, duration, dosing, and administration of CSFs? Dr. Bishal Gyawali: Yeah, I think there has been some new data in this regard that were not available in the previous guideline. For example, we have new trials testing a shorter duration of filgrastim injections compared to the standard of care. So we have some data, we call this 'de-escalation of treatment'. So we have more data supporting de-escalation of treatment. We have some data for lower dose of pegfilgrastim, we have data for lower duration of filgrastim, we have also some new data about timing of treatment, as in there has been some newer data presented about the relationship of timing of the drug and the frequency of adverse events from G-CSF such as bone pain. There is also the question about, for patients who don't live near the cancer center, can they get their pegfilgrastim shot on the day of chemo while they are in the cancer center? So all these questions that are very pragmatic and important questions, but were not answered before, we're glad that we had more evidence to talk about all these factors and give a more solid recommendation to our users of the guideline. Brittany Harvey: Definitely. And listeners can review the full list of dosing and administration recommendations in Table 2 in the guideline, and that will be linked in the show notes of the episode. So then I really want to thank you both for reviewing all of these recommendations. There's certainly a large amount of clinical questions and recommendations that you went through. I'd like to next ask, in your view, what is the importance of this updated guideline and how will it impact both clinicians and patients? Dr. Bishal Gyawali: I think the importance of this updated guideline is that, as mentioned before, we talk about newer data that have come up with regards to not just the most important two questions as in when to use it as primary prophylaxis and when to use it as secondary prophylaxis and when to use it as treatment, but also with regards to the duration and timing and dosing and multiple options and how these all factors as well as patient-related factors should be combined to make an informed decision, the most appropriate decision for the patient. And as mentioned before, we have the GRADE tables that were not in the previous version of this guideline. So I think even those users that are familiar with the 2015 guideline, I think they will find very novel content in this new updated guideline, and they will find it useful for their practice. I would encourage the readers to not only read the headlines of the box recommendations, but also read the full text of these guidelines because we have worked really hard to incorporate the latest evidence and also interpret them contextually. The discussion regarding de-escalation, patient considerations, cost implications; usually, people just skip these portions when they read a guideline. But I think these are also one of the most important paragraphs in our guideline, so they have been written with very careful thought, and I think reading the whole guideline is very much worth your time. Dr. Tessa Cigler: As you can imagine, I agree completely, having just spent several months thinking about these guidelines and all their nuances. Brittany Harvey: Certainly, this guideline is definitely a very comprehensive update, and that nuance in the manuscript is really important for clinicians to understand and read through and understand when it's appropriate to make certain decisions. So then to wrap us up, I'd like to ask, what are the outstanding questions and active research areas regarding the use of white blood cell growth factors in patients with cancer? Dr. Tessa Cigler: As you all know from clinical practice and that we've said several times already in this podcast is that the risk factors for the development of complications of febrile neutropenia are still not clearly worked out. And one of the things that is, I think, really needed in clinical practice is the development of predictive algorithms or biomarkers to really allow us to understand who might be more at risk and to allow for the clinician to be able to tailor the use of G-CSF as needed. Brittany Harvey: Yes, and so we'll look forward to future updates in this space to inform new recommendations and an updated guideline in the future. So I want to thank you both so much for your work to develop this comprehensive guideline. It was certainly a lot of effort, and thank you for your time today, Dr. Gyawali and Dr. Cigler. Dr. Tessa Cigler: Oh, my pleasure. It's nice to be here and to speak with you all. Dr. Bishal Gyawali: Yeah, it was great to speak with both of you but also through you to the audience, and we had a great time. Thank you. Brittany Harvey: And then finally, thank you to all of our listeners for tuning in to the ASCO Guidelines podcast. To read the full guideline, go to www.asco.org/supportive-care-guidelines. You can also find many of our guidelines and interactive resources in the free ASCO Guidelines app, available in the Apple App Store or the Google Play Store. If you have enjoyed what you've heard today, please rate and review the podcast and be sure to subscribe so you never miss an episode. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.

Are you "Grade A Supply" without even knowing it?Most people think narcissists target "broken" people. As a self-aware narcissist, I'm telling you that's a lie. We want the best. We want the person with the biggest heart, the most success, and the most to give. But there is a dark side to being "the best"—to a narcissist, you are a high-value asset that is ultimately replaceable.IN THIS LIVE, WE ARE DISCUSSING:The Anatomy of Grade A Supply: The 4 traits that make you an irresistible target.The "Reflector" Effect: How we use your light to hide our darkness.The Cold Truth on Replaceability: Why we can move on in 24 hours even after you gave us everything.Breaking the Pedestal: How to stop being "supply" and start being a person again.If you've ever felt like you were "special" to them only to be discarded like trash, this Live is for you.Connect with Lee:My Courses: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://courses.mentalhealness.net⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ 1-on-1 Coaching Calls: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://link.me/mentalhealness⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠All My Link: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://beacons.page/mentalhealness ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Follow on Instagram/TikTok: @mentalhealnesssIf this episode helped you gain clarity, please leave a 5-star review on Spotify! It helps others find the validation they need to heal.

The boys in Orange and Blue are back and so are Adam and Adam to recap Matchday 1.Cincy grabs a 2-0 victory over Atlanta to start the campaign and there are no shortages of storylines and performances to to talk about.There were several candidates for Man of the Match and Adam perhaps picked a controversial one, but the stats back it.Listen up!!!!@TheKingAdRock73 @NinoOne @sbucks67 @crackityFC @ComeOnYouFCC @fccincinnati @Zuhause513 @MLS #AllForCincy #FCCincy #YAL #WestEndBoys

The lights were bright, the stakes were high, and the work felt world‑shaping. Lilly stepped into national broadcast straight out of college, scaled a tiny shop into a multi‑crew operation, and answered calls when presidents landed or crises erupted—only to realize the culture fueling those wins ran on tests, temper, and control.Click HERE to learn more about DialecticsHERE ARE MORE RESOURCES FROM REAL GOOD VENTURES:Never miss a good opportunity to learn from a bad boss...Click HERE to get your very own Reference Profile.  We use The Predictive Index as our analytics platform so you know it's validated and reliable.  Your Reference Profile informs you of your needs, behaviors, and the nuances of what we call your Behavioral DNA.  It also explains your work style, your strengths, and even the common traps in which you may find yourself.  It's a great tool to share with friends, family, and co-workers.Follow us on Instagram HERE and make sure to share with your network!Follow us on X HERE and make sure to share with your network!Provide your feedback HERE, please!  We love to hear from our listeners and welcome your thoughts and ideas about how to improve the podcast and even suggest topics and ideas for future episodes.Visit us at www.realgoodventures.com.  We are a Talent Optimization consultancy specializing in people and business execution analytics.  Real Good Ventures was founded by Sara Best and John Broer who are both Certified Talent Optimization Consultants with over 50 years of combined consulting and organizational performance experience.  Sara is also certified in EQi 2.0.  RGV is also a Certified Partner of Line-of-Sight, a powerful organizational health and execution platform.  RGV is known for its work in leadership development, executive coaching, and what we call organizational rebuild where we bring all our tools together to diagnose an organization's present state and how to grow toward a stronger future state. Send a text

Today on the Annie Frey Show: Grade the current state of the United States. Rep Mary Miller, Representative from Illinois 15th District joins to discuss President Trump State of the Union and Governor Pritzker. Taylor Riggs, Co-Host of The Big Money Show on Fox Business joins to talk about the state of the economy, tariffs and more. Jim Talent, Former US Senator from Missouri joins to discuss Iran and the US, if an alliance could threaten the US and more.

Grade 7 math teacher Gabriel Despatie (Ontario) shares what happened when he tried to “overlay” standards-based grading onto nine years of refined tests—and why he ultimately scrapped his assessments after realizing they were packed with filler that measured rounding, formatting, and test-taking more than the actual learning goals. Gabriel walks through the system that finally clicked: a weekly “Learning Carnival” where students work one standard at a time with three backwards-compatible performance levels (mild/medium/spicy), two questions per level, and unlimited retakes that count as mastery whenever they happen. The conversation dives into practical logistics (tracking sheets, retake flow, managing chaos), the surprising motivational impact of gamified mastery markers (smiley faces and fist pumps), and what changed when he temporarily hid percentage grades—only to see retakes drop as soon as the numbers returned. Along the way, Gabriel connects alternative grading to Building Thinking Classrooms, shares how Open Middle tasks improved assessment quality (without punishing reading comprehension), and reflects on why meaningful grading reform takes time, iteration, and community support.LinksPlease note - any books linked here are likely Amazon Associates links. Clicking on them and purchasing through them helps support the show. Thanks for your support!Building Thinking Classrooms, by Peter LiljedahlModifying Your Thinking Classroom for Different Settings, by Peter LiljedahlResourcesThe Center for Grading Reform - seeking to advance education in the United States by supporting effective grading reform at all levels through conferences, educational workshops, professional development, research and scholarship, influencing public policy, and community building.The Grading Conference - an annual, online conference exploring Alternative Grading in Higher Education & K-12.Some great resources to educate yourself about Alternative Grading:The Grading for Growth BlogThe Grading ConferenceThe Intentional Academia BlogRecommended Books on Alternative Grading:Grading for Growth, by Robert Talbert and David Clark

Connor Herson is back after an insane 3 years. Last week he proposed the world's first 5.15 trad climb, “Drifter's Escape,” a beautiful single pitch in Squamish that revolves around one of the best moves you could ask for on gear.He also talks about balancing climbing professionally with completing his masters degree, lessons he's learned from climbing with boulderers, and his philosophy of improving by climbing as much volume as he can without sacrificing difficulty.Patreon Bonus Content (join Patreon for extended cut): A look into Connor's approach to trainingWhat makes him so strong on jams and locks?Connor's bouldering aspirationsConnor and the TB2Join Patreon: HERE Follow us on Instagram: HERE Visit our podcast page: HERE

SummaryIn this Q&A roundtable, Chase Smith and Chris Bealhen talk about what to do when life gets stressful and everything feels out of control. They explain that most people panic, quit their goals, and then feel even worse. Instead, they tell you to slow down, breathe, and focus on what you can control, like meal prep, water, steps, and protein.They answer a question about wanting to throw your scale across the room. They explain that weight goes up and down for many reasons, and you need more weigh-ins each week to see the real trend. They also talk about why avoiding the scale can backfire later.Next, they talk about “bulk” vs “lean” pre-workout and explain it depends on your goal, but most people don't need different supplements for different phases. Finally, they answer a question about struggling to believe healthy habits can last forever. They remind you that you don't have to do it forever right now. You just have to do it one more day, and keep stacking small wins.Chapters(00:00) Q&A Roundtable Intro and Why People Panic When Life Gets Hard(01:05) Slow Down, Make a Plan, Focus on the Biggest Needle Driver(02:46) Your Reaction to Chaos Can Make Everything Worse(05:10) Client Story: Staying on Track During Stress(08:22) Q1: How to Stop Hating the Scale Every Weigh-In(10:14) Why You Need More Weigh-Ins for Better Data(12:00) The Scale Is Not a Grade for Your Effort(16:08) Maintenance Tip: Keep Weighing In and Set an “Oh Crap” Number(20:05) Q2: Bulk vs Lean Pre-Workout(22:55) Q3: “How Do I Believe This Can Stick for Life?”(25:02) One More Day and Shrink the Habit(29:29) Wrap Up and Submit QuestionsSUBMIT YOUR QUESTIONS to be answered on the show: https://forms.gle/B6bpTBDYnDcbUkeD7How to Connect with Us:Chase's Instagram: https://www.instagram.com/changing_chase/Chris' Instagram: https://www.instagram.com/conquer_fitness2021/Facebook Group: https://www.facebook.com/groups/665770984678334/Interested in 1:1 Coaching: https://conquerfitnessandnutrition.com/1on1-coachingJoin The Fit Fam Collective: https://conquerfitnessandnutrition.com/fit-fam-collective

Welcome back to the 272nd episode of The Cup which is our a weekly (give or take, TBD, these are unprecedented times) performing arts talk show presented by Cup of Hemlock Theatre. With the theatres on a come back we offer a mix of both reviews of live shows we've seen and continued reviews of prophet productions! For our 272nd episode we bring you a Duet Review of White Rabbit, Red Rabbit by Nassim Soleimanpour, presented by One Four One Collective, Nassim Soleimanpour Productions, and The Assembly Theatre. Co-Artistic Producer Mackenzie Horner is joined by new guest panelist Sophie Loosley-Millman to unpack this no-rehearsal, no-director, no-set theatrical experiment—where a different performer each night opens a sealed envelope and reads the script for the first time live on stage. Featuring Anand Rajaram as the performer they saw, the duo explores his unique take, the symbolism woven through the text, and whether Sophie would teach the play in her classroom.White Rabbit, Red Rabbit is playing at The Assembly Theatre (1479 Queen St. W., Toronto, ON) until February 20th, 2026. Tickets can be purchased from the following link: https://www.theassemblytheatre.com/whiterabbitredrabbit This review contains many SPOILERS for White Rabbit, Red Rabbit. It will begin with a general non-spoiler review until the [12:25] mark, followed by a more in-depth/anything goes/spoiler-rich discussion. If you intend to see the production, we recommend you stop watching after that point, or at least proceed at your own risk. Follow our panelists: Mackenzie Horner (Before the Downbeat: A Musical Podcast) – Instagram/Facebook: BeforetheDownbeatApple Podcasts: https://apple.co/3aYbBeNSpotify: https://spoti.fi/3sAbjAu Sophie Loosley-Millman – Instagram: @soph.lmFollow Cup of Hemlock Theatre on Instagram/Facebook/Twitter: @cohtheatreIf you'd like us to review your upcoming show in Toronto, please send press invites/inquiries to coh.theatre.MM@gmail.comCHAPTERS: 0:00 – Intro: Romeo's Butt 4:32 – Pre-Spoiler12:17 – SPOILERS from here on out 12:37 – Remember the Order 15:56 – Beast Fable 21:06 – Unreliable Narrators 22:34 – One of the classic blunders! 26:28 – Anand Rajaram 29:34 – Language Barrier 31:57 – Say Uncle 35:34 – Grade 1237:55 – Sign Off

In this episode of JCO Article Insights, host Dr. Melis Canturk summarizes the article, "Atezolizumab With Bevacizumab and Nonplatinum Chemotherapy for Recurrent Ovarian Cancer: Final Results From the Placebo-Controlled AGO-OVAR 2.29/ENGOT-ov34 Phase III Trial," by Harter et al. TRANSCRIPT Melis Canturk: Hello, and welcome to the JCO Article Insight. I'm your host, Melis Canturk, and today we will be discussing the JCO article, "Atezolizumab With Bevacizumab and Nonplatinum Chemotherapy for Recurrent Ovarian Cancer: Final Results From the Placebo-Controlled AGO-OVAR 2.29/ENGOT-ov34 Phase III Trial." While integrating immune checkpoint inhibitors has revolutionized the treatment of various gynecologic cancers, these agents have historically shown limited single agent activity in ovarian cancer. Despite a strong biological rationale for combining immunotherapy with chemotherapy and bevacizumab to enhance T-cell infiltration and normalized tumor vasculature, several phase III trials have failed to demonstrate a significant survival benefit in this setting. The AGO-OVAR 2.29/ENGOT-ov34 trial was launched to definitely evaluate whether adding the PD-L1 inhibitor atezolizumab to this combination could improve long-term outcomes for patients experiencing early relapse. This international, double-blind, randomized phase III trial enrolled 574 patients with epithelial ovarian, fallopian tube, or peritoneal cancer. Eligible participants had to be in their first or second relapse within 6 months of completing platinum therapy or in their third relapse regardless of the treatment-free interval. All patients received bevacizumab and an investigator selected chemotherapy backbone, either paclitaxel or doxorubicin. They were randomly assigned to receive either 840 mg of atezolizumab or a placebo every 2 weeks until disease progression or for a maximum of 2 years. The study population was an all-comer group, though patients were stratified by their PD-L1 status, previous bevacizumab use, and the number of prior treatment lines. The trial did not meet its primary end points, as the addition of atezolizumab failed to significantly improve overall survival or progression-free survival in the intention-to-treat population. For the primary end point of overall survival, the median was 14.2 months with atezolizumab compared to 13 months with the placebo. Progression-free survival was similarly insignificant, with a median of 6.4 months in the experimental arm versus 6.7 months in the control arm. Furthermore, the objective response rates were nearly identical between the groups, recorded at 40% for atezolizumab and 44% for the placebo. Interestingly, exploratory subgroup analyses revealed potential signals of benefit in specific populations, even though the overall trial was negative. Patients who had been previously treated with bevacizumab appeared to derive a greater benefit from the addition of atezolizumab than those who were bevacizumab-naïve. Additionally, outcomes seemed more favorable for patients receiving a paclitaxel chemotherapy backbone compared to those receiving doxorubicin. However, PD-L1 status did not appear to be a predictive marker for success, as hazard ratios for survival were similar regardless of whether the tumor was PD-L1 positive or negative. The safety profile of the triple combination was consistent with the known toxicities of the individual drugs. Grade 3 or higher adverse events occurred in 73% of the atezolizumab group and 70% of the placebo group. While the experimental arm saw higher incidences of immune-mediated events, such as thyroid-related issues, these were generally manageable. Serious adverse events were more frequent in the atezolizumab arm than in the placebo arm, but discontinuation rates due to toxicity were relatively low and comparable between the two groups. In conclusion, the AGO-OVAR 2.29 trial confirms that adding atezolizumab to bevacizumab and nonplatinum chemotherapy does not provide a statistically significant survival advantage for patients who receive nonplatinum chemotherapy for recurrent ovarian cancer. This study contributes to the growing body of evidence showing that immune checkpoint inhibitors have yet to find a definitive role in the standard treatment of recurrent ovarian cancer. Future research will likely focus on more sophisticated molecular stratification and the use of novel agents, such as bispecific antibodies, to overcome the challenging tumor microenvironment of low-grade serous ovarian cancer. Thank you for tuning into JCO Article Insights. Don't forget to subscribe and join us next time as we explore more groundbreaking research shaping the future of oncology. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.  

It's a heated debate every day… but no one drops the gloves. Get your daily diagnosis on the health of the Habs. The Habs Lunch with Sean Campbell and Mitch Gallo.

In this third collaboration between SIDP's Breakpoints and ESCMID's Communicable podcasts, hosts Erin McCreary and Angela Huttner invite two veteran authors of guidelines and guidances, Pranita Tamma (Philadelphia, USA) and Benedikt Huttner (WHO, Geneva, Switzerland) [1-3]. Together, they deconstruct the complex landscape of developing and implementing guidelines into digestible components: they discuss why different organizations develop guidelines and what need they hope to fulfil, the framework including the GRADE methodology under which guidelines are written, and major barriers in the uptake of guidelines. The conversation also details the distinction between guideline and guidance as well as the art and science behind formulating recommendations or suggestions, with a few anecdotal cases sprinkled in from the panel. References 1. WHO handbook for guideline development, 2nd Edition, https://www.who.int/publications/i/item/9789241548960 2. The WHO AWaRe (Access, Watch, Reserve) antibiotic book https://www.who.int/publications/i/item/9789240062382 3. IDSA 2024 Guidance on the Treatment of Antimicrobial Resistant Gram-Negative Infections, https://www.idsociety.org/practice-guideline/amr-guidance/ Learn more about the Society of Infectious Diseases Pharmacists: https://sidp.org/About Twitter: @SIDPharm (https://twitter.com/SIDPharm) Instagram: @SIDPharm (https://www.instagram.com/sidpharm/) Facebook: https://www.facebook.com/sidprx LinkedIn: https://www.linkedin.com/company/sidp/ SIDP welcomes pharmacists and non-pharmacist members with an interest in infectious diseases, learn how to join here: https://sidp.org/Become-a-Member Listen to Breakpoints on iTunes, Overcast, Spotify, Listen Notes, Player FM, Pocket Casts, Stitcher, Google Play, TuneIn, Blubrry, RadioPublic, or by using our RSS feed: https://sidp.pinecast.co/

We've seen incredible advances in medical science over the past few decades, but doctors still marvel at the complexity and intricacies of the human body and its miraculous functions. Join in as we aim to bridge science and faith, demonstrating that our eyes, heart, lungs and other body parts point to a purposeful Creator, who we call the Brains of the Operation. The series begins on Feb. 15th at Horizon's 11 a.m. Exploring Service.

In this third collaboration between SIDP's Breakpoints and ESCMID's Communicable podcasts, hosts Erin McCreary and Angela Huttner invite two veteran authors of guidelines and guidances, Pranita Tamma (Philadelphia, USA) and Benedikt Huttner (WHO, Geneva, Switzerland) [1-3]. Together, they deconstruct the complex landscape of developing and implementing guidelines into digestible components: they discuss why different organizations develop guidelines and what need they hope to fulfil, the framework including the GRADE methodology under which guidelines are written, and major barriers in the uptake of guidelines. The conversation also details the distinction between guideline and guidance as well as the art and science behind formulating recommendations or suggestions, with a few anecdotal cases sprinkled in from the panel. This episode was edited by Kathryn Hostettler and Lacy Worden. It was peer reviewed for Breakpoints by Lacy Worden and for Communicable by Ljiljana Lukić of University Hospital for Infectious Diseases in Zagreb, Croatia.  References WHO handbook for guideline development, 2nd Edition The WHO AWaRe (Access, Watch, Reserve) antibiotic book IDSA 2024 Guidance on the Treatment of Antimicrobial Resistant Gram-Negative InfectionsFurther readingESCMID AMR Guidelines, https://clinicalmicrobiologyandinfection.com/retrieve/pii/S1198743X21006790 GRADE working group, https://www.gradeworkinggroup.org/GRADE Book, https://book.gradepro.org/ IDSA's intraabdominal guidelines, https://www.idsociety.org/practice-guideline/intra-abdominal-infections/ ESCMID Manual for Clinical Practice Guidelines and Other Guidance Documents, https://www.escmid.org/guidelines-journals/guidelines/ International Consensus Guidelines for the Optimal Use of the Polymyxins https://accpjournals.onlinelibrary.wiley.com/doi/epdf/10.1002/phar.2209 American Thoracic Society guidelines on community-acquired pneumonia, https://www.atsjournals.org/doi/abs/10.1164/rccm.202507-1692ST 

Ken and Curtis preview the 2026 Red Sox ahead of their first Spring Training game later today. Are we worried about the offense? Sam Kennedy continues to say the wrong things to the media. We preview USA vs. Canada, and look back at the best calls in sports history.

Parents of Toddlers through 5th Grade

Parents of Toddlers through 5th Grade

Parents of Toddlers through 5th Grade

Fred Hoiberg has apologized about a incident involving an Iowa fan and a cell phone, we grade the apology

Episode 456, including tracks from Riot City Radio, Lawmaker, Grade 2, Micah and The Mirrors, Brad Marino, The Melmacs, The Darts, Down Division, Safety Second, D.O.A., Battle Flask, Banda AL9, and The Sh-Booms. Eric adds his upcoming releases, but is unable to make it this episode. The episode is loaded with a bunch of new music shared with us, a great album, and wrap up the show with a couple indie rock and psych-funk tracks.

Tony Baldassarre, President and CEO of UniDoc Health, has a mission to provide accessible healthcare through remote technology and a Health Cube that can be deployed in a wide range of settings. This approach integrates into existing EMR/EHR platforms and includes a healthcare professional who works with the patient in the Cube to interact with medical devices and consult remotely with a doctor. There have been successful deployments in Ukraine, Italy, and Alaska, showing a significant reduction in emergency room visits and demonstrating capabilities for specialized care and management of chronic conditions.  Tony explains, "With the UniDoc solution, what we do is not just enable a conversation between a doctor and patient - it is not just a phone or video call. We actually provide real diagnostic medical devices for doctors to conduct a comprehensive medical visit remotely, just as if the patient were in their office. The important thing is that number one, we only use real medical devices. These are medical devices that are approved by Health Canada, the FDA, and the European Union. They are the exact same medical devices that you find at a doctor's office or a hospital. So the doctors are actually conducting the visit, and the data that they're receiving is exactly the same as it would be if they were together in the office."   "So, simply what happens first and foremost is that the patient, either through the browser, the UniDoc website, or through our app, chooses a doctor, be it male, female, different races, languages, etc. Once they have the appointment confirmed by the doctor, the patient just shows up at the Health Cube at the time that they requested the appointment, and they walk in. Once inside the Cube, there's a chair and a nurse, I'll call them a nurse for generality. There's a nurse on site, and the doctor is the only person who is remote. At that point, the nurse connects the doctor to the visit, and the medical visit starts."   "We have two Cubes in Ukraine right now, actually in Kyiv and at the border of Romania and Ukraine. That's been set up there since April of this year. We've already seen over 3000 patients, and a lot of it is actually being used by people in the town and for chronic diseases. On top of that, by law in Ukraine, we had to place these Cubes by the hospitals. That's a requirement. And the hospital is actually seeing a 35% decline in people going to the emergency room."  #UniDocHealth #HealthTech #RemoteHealthcare #MedicalInnovation #Telehealth #HealthcareAccess #Telemedicine #MedicalDevices #HealthEquity #DigitalHealth #RuralHealthcare #HealthcareInnovation  UniDocHealth.com Download the transcript here

(00:00) Zolak & Bertrand start the hour by talking about Dave Schoenfield's offseason grade for the Red Sox(10:24) We discuss whether or not its fair that the Red Sox are placing huge expectations on Roman Anthony's offensive production(20:00) The guys break down the drama between the Red Sox and Fanatics.(31:01) We finish the hour with a bunch of Red Sox calls mixed in.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

On this episode of Zen and the Art of Real Estate Investing, Jonathan Greene interviews Ashley Garner, founder of ABG & Associates and a multifamily investor with more than three decades of experience. Ashley shares how growing up renovating college rentals with his banker father shaped his long-term mindset and ultimately led him to scale from small single-family properties to hundreds of apartment units across North Carolina. Ashley reflects on the transition from hands-on landlord to operator and capital raiser, explaining why scaling required him to let go of control and trust professional property management. He discusses the importance of communication systems, standardized processes, and focusing geographically to build operational leverage. The conversation also explores syndication, raising capital through relationships, and how cost segregation and bonus depreciation can dramatically enhance investor returns. Throughout the episode, Jonathan and Ashley return to a central theme: real estate is a long game. Whether it's holding properties for decades to fund long-term care, prioritizing clean and safe housing for tenants, or building trust with investors, sustainable success comes from discipline, patience, and strong relationships. In this episode, you will hear: How Ashley's early exposure to college rentals shaped his investing philosophy Why scaling required letting go of hands-on management The importance of structured communication with property managers How focusing on one state can create operational and investor advantages The mindset shift from "asking for money" to offering opportunity through syndication How cost segregation and bonus depreciation can significantly boost investor returns Follow and Review If you enjoy the show, please follow Zen and the Art of Real Estate Investing on Apple Podcasts and leave a rating and review. It helps other listeners discover these conversations and supports the show's growth. Supporting Resources Connect with Ashley: Website: http://www.abgmultifamily.com/  Youtube: http://www.youtube.com/@abgmultifamily  Facebook: http://facebook.com/ABGRealEstate  Instagram: http://instagram.com/abgrealestate  LinkedIn: https://www.linkedin.com/in/ashleybgarner/  X: http://twitter.com/ABGRealEstate  Connect with Jonathan: Website - www.streamlined.properties  YouTube - www.youtube.com/c/JonathanGreeneRE/videos  Instagram - www.instagram.com/trustgreene  Instagram - www.instagram.com/streamlinedproperties    Zillow - www.zillow.com/profile/streamlinen​j Bigger Pockets -  www.biggerpockets.com/users/jonathangreene Facebook - www.facebook.com/streamlinedproperties  Email - info@streamlined.properties   This episode was produced by Outlier Audio.

In Ep. 1 of a brand-new Jets draft preview show, host Eric Allen is joined in the studio by ESPN NFL Draft analyst to Matt Miller to talk about the Green & White and the 2026 NFL Draft. Miller touches on a plethora of topics including what QBs he has on the top of his board, how NFL-ready Alabama QB Ty Simpson is, who is the better prospect between Ohio State S Caleb Downs & Notre Dame RB Jeremiyah Love, sleeper prospects and much more.See omnystudio.com/listener for privacy information.

The Iowa State season cancellation mystery finally has an answer—at least from the administration. We dive into the internal conflicts, the AD's letter to families, and why the "safety" claims don't add up. Plus, we compare the Winter Olympics to gymnastics: what should we steal from Figure Skating's judging and NCAA updates HEADLINES Major Update on the Iowa State Season cancellation. Read the letter here Ana Barbosu whereabouts investigation Elite Season Begins! CHAPTERS 0:00 Intro: The 2026 Elite Season Begins 1:14 The Bileses: Jonathan Owens Theft Attempt in Milan 3:53 Iowa State Scandal: Why the Season Was Really Cancelled 10:43 Breaking: Ana Barbosu Under Investigation (Whereabouts Violations) 14:25 2026 Elite Kickoff: Winter Cup & Cottbus World Cup Preview 18:35 Winter Olympics: A Gymnast's Perspective 21:01 What Gymnastics Must Learn From Figure Skating 35:42 The Case for a "Grade of Execution" (GOE) Judging System 50:15 Why Gymnastics Needs Live Technical Scoring Boxes 1:05:10 Commentary & Artistry: We Need "Johnny Weir Energy" 1:14:25 Olympic Traditions: Throwing Stuffed Animals & Logistics 1:25:40 NCAA Update: The Race for Perfect 10s & Regional Rankings 1:38:15 Comedy Award of the Week: The Beam Save 1:41:34 Join Us for College & Cocktails: LSU vs. Oklahoma UP NEXT Fantasy Gymnastics podcast every Wednesday College & Cocktails: Friday,  7:30 pm Pacific where we will watch LSU at Oklahoma on ESPN2 2026 Cocktail and Mocktail menu here Add exclusive Club Content to your favorite podcast player (instructions here). UPDATES Attention! We are giving away 2 tickets to the American Cup in Las Vegas  Check us out on Bluesky NEW Team Bronze Design in the store! Join our Live Shows Replay tickets on sale for our fundraiser show with all the Tea from Cecile Landi 2026 Live Show Season Pass is now available, 4 shows for the price of 3 SUPPORT OUR WORK Club Gym Nerd: Join Here Fantasy: 2026 College Fantasy Game now open all season with weekly winners Merch: Shop Now Newsletters The Balance Beam Situation: Spencer's GIF Code of Points Gymnastics History and Code of Points Archive from Uncle Tim Resistance Resources Thanks to our Sponsor:  Limited Time Offer – Get Huel today with my exclusive offer of 15% OFF online with my code [GymCastic15] at huel.com/[GymCastic15]. New Customers Only. Thank you to Huel for partnering and supporting our show!      

What grade would you give Cooper Flagg 2/3 of the way through his rookie season? full 924 Wed, 18 Feb 2026 18:41:21 +0000 zI5hJzOEhoabEYtTF8WNTTGUZO9ACuDL nba,dallas mavericks,cooper flagg,sports The K&C Masterpiece nba,dallas mavericks,cooper flagg,sports What grade would you give Cooper Flagg 2/3 of the way through his rookie season? K&C Masterpiece on 105.3 The Fan 2024 © 2021 Audacy, Inc. Sports False https://play

In 2019, Illinois' legal weed legislation was hailed as the “most equity-centric” cannabis law in the country. But in reality, those promises didn't quite materialize. Chicago Reporter's Sara Cooper joins host Jacoby Cochran and executive producer Simone Alicea to talk about what the state got wrong about legal weed. Plus, they're catching up on some legislation to watch in Springfield, including data center regulation and the latest in Bears stadium drama. Want some more City Cast Chicago news? Then make sure to sign up for our daily newsletter. Follow us @citycastchicago You can also text us or leave a voicemail at: 773 780-0246 Learn more about the sponsors of this Feb. 17 episode: Chicago Board of Election Commissioners Access Contemporary Music — Use promo code PIANO for 20% off Window Nation South By Southwest — Unlock a 10% discount on your Innovation Badge when you use code citycast10 Become a member of City Cast Chicago. Interested in advertising with City Cast? Find more info HERE

Advocacy can feel intimidating, especially as a student. But what if your future scope of practice, reimbursement, autonomy, and even student loan access are being shaped right now? Mackenzie and Levi recently attended Lobby Day in Florida and Nicolas went to Capitol Day in Arizona. Kelsey asks them about their experiences and advice for other SRNAs. You'll learn more about what advocacy events actually look like, how they prepared, what surprised them most, and the powerful realization that legislators often know very little about what CRNAs truly do. Showing up to advocate isn't just crucial for policy, it's also important for every SRNA's professional journey.    Here's some of what we discuss in this episode:

Marshall Harris and Russ Dorsey discussed a variety of sports topics in the 5 On It segment.

Most leads sound "good" until you start pulling on the threads. Nick and Tyler roleplay four common inquiry types and show how to spot risk early, protect your time, and decide whether it's pre-con, a small feasibility study, or a hard pass. Show Notes: 00:00 Cold open 00:31 Why decision makers matter 01:54 Sponsor: Anderson 05:30 Sponsor: Harness Workwear 09:13 Feasibility vs pre-con 09:35 Lead intake template & newsletter 22:36 Call 1: Referral lead 28:27 Call 2: Tight budget lead 39:47 Call 3: Facebook rush job 48:41 Call 4: Dream home lead 53:37 When the timeline is a deal-breaker 01:01:10 Wrap Video Version:https://youtu.be/aBTqwssCt80   Partners:  Andersen Windows Harnish Workwear  Use code H1025 and get 10% off their H-label gear   The Modern Craftsman: linktr.ee/moderncraftsmanpodcast Find Our Hosts:  Nick Schiffer  Tyler Grace  Podcast Produced By: Motif Media